Benefits of Therapeutic Drug Monitoring of First Line Antituberculosis Drugs
, , , , , und
20. Aug. 2020
Über diesen Artikel
Online veröffentlicht: 20. Aug. 2020
Seitenbereich: 45 - 55
Eingereicht: 29. Apr. 2020
Akzeptiert: 28. Mai 2020
DOI: https://doi.org/10.2478/acm-2020-0006
Schlüsselwörter
© 2020 K Prso et al., published by Sciendo
This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Tuberculosis is an airborne infectious disease that remains a huge global health-related issue nowadays. Despite constant approvals of newly developed drugs, the use of first-line antituberculosis medicines seems reasonable in drug-susceptible